
News|Articles|December 19, 2023
- MHE December 2023
- Volume 33
- Issue 12
State of the Industry: Key Issues, Technology Impact, Presidential Campaign Focus, and Challenges Ahead in 2024
We conducted our annual State of the Industry survey in the early part of November 2023. The survey had 432 respondents, of whom 56% self-reported working for a payer organization (pharmacy benefit manager, insurer or self-insured employer), 34% for a provider organization and the remainder for government or an unspecified “other” category.
Advertisement
Articles in this issue
over 2 years ago
The Best Hope for Eradicating HCVover 2 years ago
Biosimilars are Ascendantover 4 years ago
ICER: More Transparency of Drug Coverage Policies NeededAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
3
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
4
Recent COVID vaccination cuts household transmission by half
5






















